-
Ranbaxy reports Q1
GURGAON, India — First-quarter consolidated sales for generic drug maker Ranbaxy Labs totaled $736 million, the company reported last week.
The company said the quarter's sales marked a 55% increase over the year-ago period, when sales totaled $474 million. U.S. sales for the company totaled $416 million, up from $170 million in first quarter 2011. Ranbaxy attributed its sales boost to the launch of generic Lipitor (atorvastatin), as well as sales of generic Caduet (amlodipine and atorvastatin).